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Abstract In the aging society, it is important to identify
very old persons at high risk of functional decline, cardio-
vascular disease and mortality. However, traditional risk
markers lose their predictive value with age. We investi-
gated whether plasma N-terminal pro-B-type natriuretic
peptide (NT-proBNP) levels predict change in functional
status, cardiovascular morbidity and mortality in very old
age. Here we present an observational prospective cohort
study (Leiden 85-plus Study, 1997–2004) in a population-
based sample of 560 individuals aged 85 years with a 5-
year complete follow-up for functional status, cardiovas-
cular morbidity and cause-specific mortality. Median NT-
proBNP for men was 351 pg/ml (cutoff values for low-
medium tertiles 201 pg/ml and medium-high tertiles
649 pg/ml) and, for women, 297 pg/ml (cutoffs 204 and
519 pg/ml, respectively). During the 5-year follow-up,
participants with high NT-proBNP had an accelerated
cognitive decline and increase of activities of daily living
(ADL) disability over time (all at p<0.01) and an increased
risk of incident heart failure [hazard ratio (HR) 3.3 (95 %
confidence interval (CI) 1.8–6.1)], atrial fibrillation [HR
4.1 (2.0–8.7)], myocardial infarction [HR 2.1 (1.2–3.7)],
stroke [HR 3.4 (1.9–6.3)], cardiovascular mortality [HR
5.5 (3.1–10)], non-cardiovascular mortality [HR 2.0 (1.4–
3.0)] and all-cause mortality [HR 2.9 (2.1–4.0)], indepen-
dent of other known risk markers. All results remained
similar after exclusion of participants with heart failure at
baseline. In very old age, high-NT-proBNP levels predict
accelerated cognitive and functional decline, as well as
cardiovascular morbidity and mortality. Results suggest
that NT-proBNP can help clinicians to identify very old
people at high risk of functional impairment and incident
cardiovascular morbidity.
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Background
In very old age, cardiovascular disease is an important
cause of disability, morbidity and mortality (Laslett et al.
2012; Murray et al. 2012). In recent decades, research
into new risk markers for cardiovascular disease
(Kavousi et al. 2012; Kistorp et al. 2005; Zethelius
et al. 2008; Melander et al. 2009; Wang et al. 2006;
Pikula et al. 2012) has shown that N-terminal pro-B-
type natriuretic peptide (NT-proBNP) is not only a
marker of heart failure but also a promising risk marker
for the development of cardiovascular disease and mor-
tality, both in primary and secondary preventions (Nadir
et al. 2012; Welsh et al. 2013; Campbell 2008; Di
Angelantonio et al. 2009; Olsen et al. 2007;
Wannamethee et al. 2011; Marz et al. 2007) However,
data in older populations are scarce (Ueda et al. 2003;
Vaes et al. 2009a; Valle et al. 2005) and have sometimes
been reported exclusively for secondary prevention (van
Peet et al. 2013a). As traditional risk markers gradually
lose their predictive value with age (Uthoff et al. 2010;
de Ruijter et al. 2009; van Peet et al. 2013b), NT-
proBNP may become an increasingly important risk
marker for cardiovascular disease and mortality in older
age groups (Ueda et al. 2003; Vaes et al. 2009a, b; Valle
et al. 2005). Since, in old age, preservation of function-
ing and independency, and not morbidity and mortality
per se, has become growingly important, associations of
new risk markers with (changes in) functional status and
cognitive decline are also of paramount interest. Few
associations of NT-proBNP with cognitive function and
functional decline have so far been observed (Feinkohl
et al. 2012; Daniels et al. 2011; Kerola et al. 2010;
Hiltunen et al. 2013), and in very old age, the predictive
value of NT-proBNPwith regard to changes in activities
of daily living (ADL) functioning and cognition over
time is still unknown.
NT-proBNP is a polypeptide belonging to the natriuret-
ic peptide family. The main source of synthesis and secre-
tion is the ventricular myocardium, initiated by ventricular
wall stress caused by pressure and/or volume overload
(Weber and Hamm 2006). NT-proBNP is highly elevated
in heart failure patients (Maisel and Daniels 2012; Vaes
et al. 2009b; Groenning et al. 2004). Levels of NT-proBNP
are also increased in acute coronary syndrome, stable
angina pectoris, pulmonary embolism, atrial fibrillation,
left ventricular hypertrophy, chronic obstructive pulmo-
nary disease, and renal dysfunction (Weber and Hamm
2006; DeFilippi et al. 2008). In the elderly, including the
presumed ‘healthy’ elderly, plasma levels of NT-proBNP
are generally elevated (Alehagen et al. 2007; Rutten and
Hoes 2008). Alterations in cardiac structure or function,
such as age-related myocardial fibrosis and subtle diastolic
dysfunction not detectable by current techniques, aswell as
reduced renal clearance, have been suggested to be in-
volved (Weber and Hamm 2006; DeFilippi et al. 2008).
These subtle cardiac changes, although not leading to overt
clinical disease, might already influence functional status
(Suwa and Ito 2009; Ueda et al. 2003) and predispose for
incident cardiovascular disease and functional deteriora-
tion. However, possible associations with the development
of cognitive and functional impairment in very old age
have not yet been studied.
In this study on individuals aged 85 years with a 5-
year complete follow-up, we investigated cross-
sectional and longitudinal associations of plasma NT-
proBNP with cognitive function, ADL disability, well-




The Leiden 85-plus Study is an observational, prospec-
tive population-based study of inhabitants of the city of
Leiden, the Netherlands. Between September 1997 and
September 1999, all inhabitants of Leiden, born be-
tween 1912 and 1914, were asked to participate from
their 85th birthday onwards. There were no exclusion
criteria. From the 705 people who were eligible, 92
refused participation and 14 died before enrollment. A
total of 599 (87 %) people gave informed consent and
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were enrolled. At baseline and yearly up to the age of
90, the participants were visited at their place of resi-
dence to take questionnaires, functional tests, and blood
samples and to record an ECG. At baseline, medical
history was obtained from the participant’s general prac-
titioner or nursing home physician, and between age 85
and 90 incident events were obtained yearly.
The Medical Ethics Committee of the Leiden
University Medical Center approved the study, and all
participants provided informed consent.
NT-proBNP
Plasma level of NT-proBNP was determined with a
chemiluminescent enzyme immunoassay (CLEIA) pro-
cedure (Roche, Switzerland) and was carried out on a
PATHFAST (Mitsubishi Chemical Medience Corp.,
Tokyo, Japan). For the assay, 50 μl citrate-plasma was
mixed with 30 μl phosphate-buffered saline, and 50 μl
of the mixture was used. The final results were corrected
for this dilution (* 8/5) and the dilution in the citrate tube
(* 10/9). Detection range was 15–30,000 pg/ml and the
coefficient of variation was <5 %.
Outcomes
Functional status
At baseline and annually during the 5-year follow-up,
cognitive function was assessed by the Mini-Mental
State Examination (MMSE), with scores ranging from
0 to 30 points (optimal) (Tombaugh and McIntyre
1992). Disability was assessed with the activities of
daily living (ADL) items from the Groningen Activity
Restriction Scale with scores ranging from 9 (optimal)
to 36 points. At baseline, we dichotomized the answers
into a score of 0 (‘cannot’ or ‘only with help from
others’) or 1 (‘yes, fully independently’, with or without
difficulty). Disability in ADL was considered present
when a participant responded ‘cannot’ or ‘only with
help from others’ on at least one ADL item. Subjective
well-being was tested with a visual analogue scale
(Cantril) in those with MMSE of >18 points, scores
ranging from 0 to 10 (optimal) (Cantril 1965). At base-
line, poor well-being was considered present if Cantril
was <7 points. Depressive symptoms were also mea-
sured in participants with MMSE of >18 points using
the 15-item Geriatric Depression Scale (GDS-15), with
scores ranging from 0 (optimal) to 15 points (de Craen
et al. 2003). At baseline, depression was considered
present with a GDS score of ≥5.
Cardiovascular disease
The general practitioner or nursing home physician of
each participant was interviewed about the patient’s
medical history, using standardized questionnaires, in-
cluding questions on present and past cardiovascular
morbidities, at baseline and annually up to age of
90 years. Specific cardiac diagnoses at baseline were
defined as the presence of a medical history of heart
failure, atrial fibrillation, angina, myocardial infarction
(MI), transient ischemic attack, stroke, intermittent clau-
dication or surgery for arterial disease, or as the presence
of atrial fibrillation (Minnesota Code 8-3-1) or a prior
MI (Minnesota Code 1–1 or 1–2, excluding 1-2-8) on
the ECG. ECGs were recorded yearly. Incident heart
failure was defined by newly diagnosed heart failure
according to the primary care physician. Incident atrial
fibrillation was defined as the appearance of Minnesota
Code 8-3-1 on the ECG. Annually, incident fatal and
non-fatal MIs were gathered using clinical data from the
primary care physician, ECGs and death registration
forms. Incident MI on the ECG was defined as the
appearance of Minnesota Code 1–1 or 1–2, or
Minnesota Code 1–3 in combination with the first ap-
pearance ofMinnesota Code 5-x in the samemyocardial
area (Macfarlane and Latif 1996). All incident MIs on
the ECG were visually confirmed by an expert in
electrocardiophysiology. A fatal incident MI was cate-
gorized by cause of death codes I21-I23 (ICD-10).
Information on incident stroke was collected annually
from the primary care physician. A fatal incident stroke
was categorized by cause of death codes I61-I69 (ICD-
10).
Mortality
All participants were followed for mortality until
the age of 90 years. Dates and cause of death
were obtained from civic and national registries.
Causes of death were divided into cardiovascular
causes ( ICD-10 codes I00- I99) and non-
cardiovascular causes (all other ICD-10 codes).
Assignment of cause of death was done blinded
for baseline and follow-up study data.
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Combined endpoint
The combined endpoint consisted of the 5-year inci-




Pharmacists provided detailed information on all medi-
cation used by the participants. These included blood-
pressure-lowering drugs (β-blockers, ACE inhibitors,
d i u r e t i c s and ca l c i um channe l b lo cke r s ) ,
anticoagulants/aspirin, and lipid-lowering drugs.
Traditional risk markers
Blood pressure was measured on two occasions with a
mean interval of 2 weeks. The mean of the measured
systolic values was used for the analyses. Serum con-
centrations of total cholesterol and high-density lipopro-
tein were analysed on fully automated computerized
analysers (Hitachi 747 and 911, Hitachi, Tokyo,
Japan). Diabetes mellitus was considered present when
listed in the medical records of the participant’s physi-
cian, when non-fasting glucose concentrations were
≥11.0 mmol/l, or when a participant was taking antidi-
abetic medication according to pharmacists’ records. All
participants were interviewed about past and present
smoking habits and were considered as smokers if they
were current smokers of cigarettes, cigars or pipes.
Possible confounding factors in relation to NT-proBNP
Body mass index (BMI) at age of 85 years was assessed
bymeasuring height and weight. Modification of Diet in
Renal Disease (MDRD) was calculated as follows:
MDRD (ml/min/1.73 m2)=186×(serum creatinine
(μmol/l) / 88.4)−1,154×age (in years)−0,203×0.742 (for
females).
Data analysis
In line with the literature (Di Angelantonio et al. 2009),
participants were ranked into tertiles (low, middle and
high NT-proBNP) based on plasma NT-proBNP level at
baseline, and sex. Odds ratios (ORs) with corresponding
95 % confidence intervals (CIs) were calculated for the
presence of functional impairment, cardiovascular risk
markers and cardiovascular disease at baseline, using
binary logistic regression analysis with the low-NT-
proBNP group as reference group.
We used linear mixed models to assess the associa-
tion of NT-proBNP with cognitive function (MMSE),
ADL disability, well-being, and depression over time.
The low-, middle- and high-NT-proBNP groups were
plotted using Kaplan-Meier curves for all-cause mortal-
ity during the 5-year follow-up. Cumulative incidences
of cardiovascular mortality were calculated and plotted,
accounting for the competing risk of non-cardiovascular
mortality, using the two-step process described by
Satagopan et al. (Satagopan et al. 2004; Verduijn et al.
2011). For comparison, we used the log rank test.
Hazard ratios (HR) were calculated (with corresponding
95 % CIs), for 5-year cardiovascular morbidity (heart
failure, atrial fibrillation, fatal and non-fatal MI, fatal
and non-fatal stroke) and cause-specific mortality for the
NT-proBNP groups, using a Cox proportional hazards
model. The p value for trend was calculated with the
NT-proBNP groups as a covariate.
Next, we constructed prediction models for the com-
bined endpoint of cardiovascular events and cardiovas-
cular mortality, with (1) only the traditional risk markers
(reference model; sex, blood pressure, total cholesterol,
high-density lipoprotein (HDL) cholesterol, history of
diabetes, current smoking) and with (2) the traditional
risk markers plus (log-transformed) NT-proBNP. We
computed for each participant the linear predictor score
(X-β), representing their individual predicted risk of the
combined endpoint cardiovascular events and cardio-
vascular mortality, using Cox proportional hazards
models, all adjusted for sex. For this combined end-
point, C-statistics and receiver operating characteristic
(ROC) curves with p values and 95 % confidence inter-
vals were calculated (1) of the model with the traditional
risk markers (referencemodel) and (2) of the model with
the traditional risk markers plus (log-transformed) NT-
proBNP. We also calculated the category-less net reclas-
sification improvement (NRI) regarding the combined
endpoint, comparing the model including (log-
transformed) NT-proBNP to the reference model
(Pencina et al. 2010; Pencina et al. 2011).
Sensitivity analyses
First, we excluded participants with heart failure at
baseline and repeated the analyses with linear mixed
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models for functional parameters, and Cox regression
for incident cardiovascular morbidity and mortality.
Second, we repeated our analyses with linear mixed
models adjusted for traditional risk markers (sex, sys-
tolic blood pressure (BP), total cholesterol, HDL cho-
lesterol, history of diabetes mellitus and current
smoking) and possible other known confounders
(BMI, MDRD, medication for hypertension), as well
as adjusted for the presence of cardiovascular disease
or of cerebrovascular disease, respectively. Third, we
calculated Odds ratios (ORs) with corresponding 95 %
confidence intervals for the presence of functional im-
pairment, adjusted for the presence of cardiovascular
disease at baseline and adjusted for cardiovascular dis-
ease plus low income (net monthly income of
≤750€) at baseline. Fourth, we calculated HRs
for incident cardiovascular morbidity and mortality,
adjusted for (a) traditional risk markers, (b) tradi-
tional risk markers plus possible other known con-
founders, and (c) all these plus prevalent cardio-
vascular disease. Fifth, we repeated the fully ad-
justed analyses with log-transformed continuous
NT-proBNP.
Data analysis was performed using SPSS 20 for
Windows (SPSS Inc., Chicago, IL, USA).
Results
Baseline characteristics
NT-proBNP was determined in 560 of the 599
participants. Missing NT-proBNP values were
completely at random. Sociodemographic, func-
tional and clinical characteristics are described in
Table 1. The majority of participants were living
independently, without severe cognitive impairment
and subjectively well. Prevalence of cardiovascular
morbidity was high. Median NT-proBNP for men
was 351 pg/ml (cutoff values for low-medium
tertiles 201 pg/ml and medium-high tertiles
649 pg/ml) and, for women, 297 pg/ml (cutoffs
204 and 519 pg/ml, respectively).
Baseline associations of plasma NT-proBNP levels
with functional and cardiovascular characteristics
Table 2 shows the cross-sectional associations of low,
middle and high plasma NT-proBNP with functional
status and cardiovascular characteristics. Higher levels
of NT-proBNP were associated with cognitive impair-
ment [ORhigh vs low 2.2 (95 % CI 1.2–3.8)], ADL dis-
ability [ORhigh vs low 2.4 (1.5–3.8)] and all specific
cardiac diagnoses at baseline. The relation of NT-
proBNP with atrial fibrillation [ORhigh vs low 22 (6.6–
72)] was even stronger than its relation with heart failure
[ORhigh vs low 4.9 (2.4–10)].




Women 372 (66 %)
Net monthly income >750€ 271 (49 %)
Post primary school education 195 (35 %)
Non-institutionalized living 458 (82 %)
Functional status
Cognitive impairment (MMSE≤18) 90 (16 %)
Dependent in daily livinga 147 (26 %)
Poor well-being (Cantril <7)b (n=463) 108 (23 %)
Depression (GDS-15≥5)b (n=466) 73 (16 %)
Cardiovascular characteristics
Cardiovascular morbidity present 305 (55 %)
Atrial fibrillation 56 (10 %)
Angina 106 (19 %)
Myocardial infarction 91 (16 %)
Heart failure 70 (13 %)
Transient ischemic attack 72 (13 %)
Stroke 56 (10 %)
Intermittent claudication 34 (6 %)
Surgery for arterial disease 37 (7 %)
Medication use
Blood-pressure-lowering drugsc 319 (57 %)
Anticoagulantsd 157 (28 %)
Lipid-lowering drugs 6 (1 %)
Traditional risk factors
Hypertensione 324 (58 %)
Systolic BP (mmHg) 155 (143–166)
Total cholesterol (mmol/l) 5.7 (4.9–6.4)
HDL cholesterol (mmol/l) 1.3 (1.0–1.6)
Diabetesf 90 (16 %)
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Functional status over time
Figure 1 and Table 3 present the associations of NT-
proBNP with cognitive impairment, ADL disability,
general well-being and depressive symptoms over time.
Compared to participants with low NT-proBNP, partic-
ipants with high NT-proBNP not only had a lower
MMSE and higher ADL disability score at baseline
but also showed an accelerated annual decrease in
MMSE score (−0.23 points per year, p<0.01) and ac-
celerated increase in ADL disability score (0.49 points
per year, p<0.001). NT-proBNPwas not associatedwith
well-being. Depressive symptoms increased over
time in participants in the high tertile of NT-
proBNP but were not significantly different from
participants in the low tertile.
Risks of cardiovascular morbidity and mortality
Table 4 presents absolute numbers of events and HRs
for incident atrial fibrillation, MI, stroke, cardiovascular
and all-cause mortality, all dependent on tertiles of plas-
ma NT-proBNP at baseline. Compared to that in the
low-NT-proBNP group, the HR for heart failure in the
group with high NT-proBNPwas 3.3 (95 %CI 1.8–6.1),
for atrial fibrillation 4.1 (95 % CI 2.0–8.7), for MI 2.1
(95 % CI 1.2–3.7), for stroke 3.4 (95 % CI 1.9–6.3), for
cardiovascular mortality 5.5 (95 % CI 3.1–10), for non-
cardiovascular mortality 2.0 (95 % CI 1.4–3.0), and for
all-cause mortality 2.9 (95 % CI 2.1–4.0).
Figure 2 presents the cumulative incidence of 5-year
cardiovascular mortality, adjusted for the competing risk
of non-cardiovascular mortality, and Kaplan-Meier
curves for all-cause mortality for gender-specific tertiles
of NT-proBNP (log rank all at p<0.001).
We estimated C-statistics and created ROC curves for
the traditional risk markers (referencemodel) and for the
traditional risk markers plus NT-proBNP, with the com-
bined endpoint of 5-year cardiovascular events (MI and
stroke) and cardiovascular mortality as predicted out-
come (Fig. 3). The combination of traditional risk
markers had a C-statistic of 0.577 (0.525–0.628).
Addition of NT-proBNP increased the C-statistic to
0.673 (0.624–0.721), with a p value for Δ C-statistic of
<0.001. This means that the model including NT-
proBNP better separates those who will develop the
combined endpoint from those who will not.
The category-less net reclassification improvement
(NRI) with addition of NT-proBNP to the traditional
risk markers was 45% (p<0.001), indicating that nearly
half of the participants were correctly reclassified, when
NT-proBNP was added to the model with the traditional
risk markers.
Sensitivity analyses
After exclusion of participants with prevalent heart fail-
ure at baseline, the association of NT-proBNP with
cognition (MMSE) and ADL disability over time and
HR for incident cardiovascular disease and mortality
remained similar (data not shown). The association of
NT-proBNP with cognition and ADL disability over
time remained similar and significant after adjustment
for all traditional risk markers (sex, systolic BP, total
cholesterol, HDL cholesterol, history of diabetes
mellitus and current smoking) and for traditional risk
markers plus BMI, MDRD and medication for hyper-
tension, as well as after adjustment for all these plus the
presence of cardiovascular or cerebrovascular disease at
baseline, respectively (online supplementary Table 5).
Cross-sectional associations of NT-proBNP with func-
tional status did not materially change after adjustments
for the presence of cardiovascular disease and for car-
diovascular disease plus low income at baseline. After
adjustment for all traditional risk markers, for traditional
risk markers plus BMI, MDRD and medication for
Table 1 (continued)
n=560
Possible NT-proBNP influencing factors
BMI >25 kg/m2 374 (69 %)
MDRD (ml/min) 59 (50–68)
Data presented as n (%) for categorical variables and median
(IQR) for continuous variables
MMSE Mini-Mental State Examination, GDS Geriatric Depres-
sion Scale, BP blood pressure, HDL high-density lipoprotein,
MDRD Modification of Diet in Renal Disease, BMI body mass
index
aDependent on ≥1 activity of daily living
bAssessed only in participants with MMSE >18
cUse of ß-blockers, ACE inhibitors, diuretics or calcium channel
blockers as reported by the participants’ pharmacists
d Anticoagulants or aspirin
e RR ≥160 systolic at baseline or a history of hypertension
f History of diabetes, antidiabetic medication use or non-fasting
glucose ≥11 mmol/l
g Current smoker of cigarettes, pipe or cigars
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n (%) OR n (%) OR n (%) OR
Functional status
Cognitive impairment (MMSE ≤18) 22 (12) 1 26 (14) 1.2 (0.65–2.2) 42 (23) 2.2 (1.2–3.8) 0.005
Dependent in daily livingb 35 (19) 1 46 (25) 1.4 (0.85–2.3) 66 (36) 2.4 (1.5–3.8) <0.001
Poor well-beingc (Cantril <7) (n=463) 38 (24) 1 33 (21) 0.84 (0.50–1.4) 37 (26) 1.1 (0.68–1.9) 0.64
Depressionc (GDS-15≥5) (n=466) 29 (18) 1 23 (14 0.76(0.42–1.4) 21 (15) 0.79 (0.43–1.5) 0.43
Cardiovascular characteristics
Cardiovascular morbidity 72 (39) 1 84 (45) 1.3 (0.84–1.9) 149 (80) 6.2 (3.9–9.8) <0.001
Atrial fibrillation 3 (2) 1 4 (2) 1.3 (0.29–6.0) 49 (26) 22 (6.6–71) <0.001
Angina 22 (12) 1 27 (15) 1.3 (0.69–2.3) 57 (31) 3.3 (1.9–5.7) <0.001
Myocardial infarction 16 (9) 1 27 (14) 1.8 (0.92–3.4) 48 (26) 3.6 (2.0–6.7) <0.001
Heart failure 10 (5) 1 19 (10) 2.0 (0.89–4.4) 41 (22) 4.9 (2.4–10) <0.001
Transient ischemic attack 17 (9) 1 25 (13) 1.5 (0.78–2.9) 30 (16) 1.9 (0.99–3.5) 0.054
Stroke 14 (8) 1 17 (9) 1.2 (0.57–2.5) 25 (13) 1.9 (0.94–3.7) 0.069
Intermittent claudication 6 (3) 1 10 (5) 1.7 (0.60–4.7) 18 (10) 3.2 (1.2–8.3) 0.011
Surgery for arterial disease 7 (4) 1 9 (5) 1.3 (0.64–3.5) 21 (11) 3.2 (1.3–7.7) 0.005
Medication use
Blood-pressure-lowering drugsd 92 (50) 1 101 (54) 1.2 (0.77–1.7) 126 (67) 2.0 (1.3–3.1) 0.001
Anticoagulantse 33 (18) 1 48 (56) 1.6 (0.96–2.6) 76 (41) 3.2 (2.0–5.1) <0.001
Traditional risk factors
Hypertensionf 100 (55) 1 78 (42) 1.2 (0.78–1.8) 114 (61) 1.3 (0.86–2.0) 0.22
Cholesterol ≥5 mmol/l 149 (81) 1 133 (71) 0.58 (0.36–0.94) 129 (69) 0.52 (0.32–0.85) 0.009
HDL <1 mmol/l 36 (20) 1 37 (20) 1.0 (0.61–1.7) 56 (30) 1.8 (1.1–2.8) 0.018
Diabetes mellitush 30 (16) 1 25 (13) 0.79 (0.45–1.4) 35 (19) 1.2 (0.69–2.0) 0.52
Current smokingg 29 (16) 1 24 (13) 0.79 (0.44–1.4) 36 (19) 1.3 (0.75–1.2) 0.34
NT-proBNP influencing factors
BMI >25 kg/m2 147 (80) 1 122 (67) 0.51 (0.31–0.82) 105 (60) 0.36 (0.22–0.57) <0.001
MDRD <60 ml/min 83 (45) 1 90 (50) 1.1 (0.75–1.7) 129 (70) 2.8 (1.8–4.2) <0.001
Data are presented as odds ratios with corresponding 95 % confidence intervals; low tertile was used as reference category
NT-proBNP cutoff value between low and middle tertile: 201 pg/ml for men and 204 pg/ml for women; between middle and high tertile:
649 pg/ml for men and 519 pg/ml for women
anticoagulants or aspirin
OsR odds ratio, MMSE Mini-Mental State Examination, GDS Geriatric Depression Scale, HDL high-density lipoprotein, MDRD Modifi-
cation of Diet in Renal Disease, BMI body mass index
aGender-specific tertiles of NT-proBNP
bDependent on ≥1 activity of daily living
c Assessed only in participants with MMSE of >18
dUse of ß-blockers, ACE inhibitors, diuretics or calcium channel blockers as reported by the participants’ pharmacists
e RR ≥160 systolic at baseline or a history of hypertension
f History of hypertension according to GP or systolic BP ≥160 at baseline
gHistory of diabetes, antidiabetic medication use or non-fasting glucose ≥11 mmol/l
h Current smoker of cigarettes, pipe or cigars
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hypertension (online supplementary Table 6), as
well as after adjustment for all these plus prevalent
cardiovascular disease (online supplementary
Table 7), HRs remained similar, except for the risk
of MI in the high-NT-proBNP group, that was
lower in the fully adjusted model (HR 1.3 (95 %
CI 0.68–2.6, p=0.30)). Fully adjusted HRs with
log-transformed continuous NT-proBNP were sim-
ilar (HRs ranging from 1.3 (1.04–1.6) for fatal and
non-fatal MI to 1.9 (1.5–2.4) for cardiovascular
mortality).
Discussion
The present study shows that, in a large population-
based cohort of 85-year-old participants, higher levels
of NT-proBNP are associated with the presence of
cognitive impairment, ADL disability and cardiovas-
cular, mainly specific cardiac, disease. Moreover,
higher levels of NT-proBNP predict accelerated cog-
nitive decline and disability over time, increased inci-
dence of cardiovascular morbidity and increased car-
diovascular and non-cardiovascular mortality, even
after adjustment for other known risk markers and
previous cardiovascular or cerebrovascular disease.
These findings demonstrate that NT-proBNP can be
used to identify very old persons at high risk of
functional decline, cardiovascular morbidity and mor-
tality, which is of pivotal importance in aging popu-
lations, where preservation of independency is vital.
While traditional cardiovascular risk markers lose their
predictive value with age, the present study shows
that in very old age, NT-proBNP remains a strong
prognostic indicator for the development of cardiovas-
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low NT-proBNP   
medium NT-proBNP 
high NT-proBNP 
Fig. 1 Changes over time in cognitive function (MMSE, scores
0–30), disability (GARS, ADL scores 9–36), subjective wellbeing
(Cantril, score 0–10) and depressive symptoms (GDS 15, scores
0–15) for gender-specific tertiles of NT-proBNP, as estimated from
linear mixed models. Data are presented as means with standard
errors; p is presented for additional annual change high versus low
tertile
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Table 3 Association between NT-proBNP at the age 85 years and (changes in) functional status in participants aged 85 through 90 years
(n=560)
Cross-sectional effect Annual effect Additional annual effect
Reference group
Low NT-proBNP











MMSE −1.2 (.68) 0.089 −2.3 (.68) <0.001 −0.73 (.054) <0.001 0.093 (.074) 0.21 −0.23 (.088) 0.009
ADL disability 1.2 (.71) 0.083 2.4 (.72) 0.001 1.2 (.084) <0.001 −0.23 (.11) 0.041 0.49 (.14) <0.001
Well-beingb 0.003 (.17) 0.99 −0.15 (.18) 0.41 −0.22 (.025) <0.001 0.021 (.035) 0.56 0.033 (.047) 0.48
Depressive
symptomsb
−0.051 (.30) 0.86 0.077 (.32) 0.81 0.30 (.042) <0.001 −0.071 (.059) 0.23 0.12 (.076) 0.13
Associations were assessed by linear mixed models
NT-proBNP cutoff value between low and middle tertile: 201 pg/ml for men and 204 pg/ml for women; between middle and high tertile:
649 pg/ml for men and 519 pg/ml for women
Scale: MMSE 0–30 points, ADL disability 9–36 points
MMSEMini-Mental State Examination, ADL activities of daily living
a Gender specific tertiles of NT-proBNP
bAssessed only in participants with MMSE of >18
Table 4 Five-year risk of cardiovascular morbidity and mortality depending on plasma NT-proBNP level at age of 85 years (n=560)
Number of events (%) NT-proBNPa
Low (ref) (n=185) Middle (n=188) High (n=187) p Trend
n (%) HR n (%) HR n (%) HR
Heart failure (n=461)b 76 (14) 16(10) 1 26 (16) 1.8 (0.98-3.4) 34 (25) 3.3 (1.8-6.1) <0.001
Atrial fibrillation (n=504)c 53 (10) 10 (6) 1 20 (11) 2.1 (1.0-4.6) 23 (17) 4.1 (2.0-8.7) <0.001
Fatal and non-fatal MI 78 (14) 19 (10) 1 29 (16) 1.6 (0.90-2.9) 30 (16) 2.1 (1.2-3.7) 0.008
Fatal and non-fatal stroke 75 (13) 15 (8) 1 22 (12) 1.6 (0.81-3.0) 38 (20) 3.4 (1.9 -6.3) <0.001
Cardiovascular mortality 100 (18) 14 (8) 1 29 (15) 2.2 (1.2-4.1) 57 (31) 5.5 (3.1-10) <0.001
Non-CV mortality 158 (28) 46 (25) 1 26 (25) 1.1 (0.71-1.6) 66 (35) 2.0 (1.4-3.0) <0.001
All-cause mortality 258 (46) 60 (32) 1 75 (40) 1.3 (0.95-1.9) 123 (66) 2.9 (2.1-4.0) <0.001
Combined endpointd 174 (31) 38 (21) 1 54 (29) 1.5 (0.99-1.3) 82 (44) 3.0 (2.0-4.4) <0.001
Hazard ratios and corresponding 95 % confidence intervals were estimated by Cox proportional hazards models
NT-proBNP cutoff value between low and middle tertile: 201 pg/ml for men and 204 pg/ml for women; between middle and high tertile:
649 pg/ml for men and 519 pg/ml for women
aGender-specific tertiles of NT-proBNP
bCases with prevalent heart failure at 85 years (n=70) were excluded, with 29 missing values; low tertile n=163, middle tertile n=160, high
tertile n=138
c cases with prevalent atrial fibrillation at 85 years (n=56) were excluded; low tertile n=182, middle tertile n=184, high tertile n=138
d Combined endpoint: cardiovascular events (MI and stroke) and cardiovascular mortality
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those who will develop the endpoint and those who
will not) of the prediction model for a combined
endpoint of cardiovascular events and mortality im-
proved when NT-proBNP was added to the model
with the traditional risk markers. Since improvement
of general model performance is not easy to interpret,
we also assessed the improvement in risk prediction
on an individual level (reclassification). The net
reclassification improvement showed that nearly half
of all participants were correctly reclassified when
NT-proBNP was added to the model.
In the knowledge that the treatment gap in primary
and secondary preventions is still considerable (Garcia
et al. 2013; Kumbhani et al. 2013; Koopman et al.
2013), optimizing blood pressure, cholesterol and anti-
coagulant treatment (in the secondary prevention
Fig. 3 ROC curves for a
combined endpoint of
cardiovascular events (MI and
stroke) and cardiovascular
mortality of a model with
traditional risk markers (dotted
line) and a model with traditional
risk markers plus (log-
transformed) NT-proBNP (black
line); p value Δ <0.001, n=560
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Fig. 2 Cumulative incidence of 5-year cardiovascular mortality, adjusted for the competing risk of non-cardiovascular mortality, and
Kaplan-Meier curves for all-cause mortality for gender-specific tertiles of NT-proBNP (log rank all at p<0.001)
population) in those with a high NT-proBNP might
improve prognosis (Perreault et al. 2012; Longstreth
et al. 2013). Checking for symptoms and signs of dis-
crete cardiac dysfunction (ECG, cardiac ultrasound) in
patients with high-NT-proBNP levels might result in
early diagnosis and treatment of subtle cardiac disease
or atrial fibrillation and consequently prevent clinical
heart disease and cerebrovascular events. Clinicians
may thus use NT-proBNP for risk stratification in very
old age and thereby select patients that might benefit
most from proactive diagnostic, therapeutic and preven-
tive interventions. On the other hand, low-NT-proBNP
levels are associated with a favourable prognosis,
and clinicians might use this information in their
decisions about (not) starting or stopping medica-
tion in very old age.
Comparison with literature
To our knowledge, this is the first report on positive
associations between NT-proBNP and cognitive func-
tion and ADL disability over time in very old age. An
earlier study showed a cross-sectional association of
NT-proBNP with cognitive function in diabetic patients
aged 60–74 years (Feinkohl et al. 2012) and in
community-dwelling older adults (Daniels et al. 2011),
whereas a Finnish study observed no association of
BNP with the development of cognitive disorders in
the oldest subgroup aged 83–96 years (Hiltunen et al.
2013). However, the present study with NT-proBNP not
only showed a strong association with cognitive impair-
ment at baseline but also an association with accelerated
cognitive decline during the 5-year follow-up.
Regarding ADL disability, one study in participants
aged ≥80 years found a cross-sectional association of
NT-proBNP with ADL disability (Ueda et al. 2003);
however, to our knowledge, no association of NT-
proBNP with accelerated ADL disability over time has
yet been reported.
In the present study, as expected, plasma NT-proBNP
at baseline was mainly associated with all cardiac dis-
eases, particularly atrial fibrillation. That NT-proBNP
that is also a strong predictor for incident atrial fibrilla-
tion was not earlier observed in very old populations but
was in younger populations (Schnabel et al. 2010;
Patton et al. 2009; Rienstra et al. 2012). During the 5-
year follow-up, NT-proBNP also predicted the develop-
ment of heart failure, in line with other studies in elderly
populations (Valle et al. 2005; Rutten and Hoes 2008).
In a meta-analysis of studies in younger populations, the
relative risk for coronary heart disease and stroke was
about twofold higher for the high versus low tertile of
NT-proBNP (Di Angelantonio et al. 2009). In line with
this observation, our study in a very old population
shows a twofold increased risk for MI and an even
higher (threefold) increased risk for stroke in subjects
with high NT-proBNP. A relation of NT-proBNP and
cardiovascular and non-cardiovascular mortality has
earlier been reported in both older populations (Ueda
et al. 2003; Wallen et al. 1997; Vaes et al. 2009a, b;
Eggers et al. 2013; Beleigoli et al. 2013a) and younger
populations (Di Angelantonio et al. 2009; Wang et al.
2004; Linssen et al. 2010). In the present study, includ-
ing participants aged 85 years, we observed a twofold
increased risk of non-cardiovascular mortality, as was
shown before in nonagenarians (Vaes et al. 2009a). The
exact mechanism is not yet clear. Maybe NT-proBNP
can be seen as a general measure of decreased vitality.
Also, subclinical cardiac dysfunction as reflected in
high-NT-proBNP levels might for example in the case
of pneumonia lead to a more unfavourable course, in-
cluding death. We also observed a more than fivefold
increased risk for cardiovascular mortality in partici-
pants with high NT-proBNP. All the above-stated risks
for the development of cardiovascular disease and mor-
tality were independent of other known risk markers,
thereby highlighting the potency of NT-proBNP as a
risk marker in very old age.
In contrast with our results, in a younger population
(mean age 69 years) and with all-cause mortality as
endpoint, Beleigoli et al. observed no improvement in
discrimination and reclassification with addition of NT-
proBNP to a model with traditional risk markers
(Beleigoli et al. 2013b). This might be explained by
the already good performance of their model with tradi-
tional risk markers only (C-statistic 0.78).
Strengths and limitations
The present study has several strengths. First, our
population-based study had a high-participation rate
and no exclusion criteria, allowing our conclusions to
be generalized to the oldest old in the general popula-
tion. Second, we studied multiple relevant outcomes for
an aging population: functional status, cardiovascular
morbidity and cause-specific mortality. Finally, NT-
proBNP levels are easy to obtain in routine clinical
practice and are often already available to the physician.
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A limitation of this study is that, although all our end-
points were clinically validated, there was no central
adjudication of cardiovascular events and cardiovascu-
lar morbidity. It could also be seen as a limitation that
our prediction model was built in persons all aged
85 years. However, in fact, this increases the power of
our study, since the probability for a change in C-
statistic is now higher (because age is no longer in the
model), and this enables our results to reflect the added
value of NT-proBNP in subjects aged 85 years. Another
limitation could be that we did not measure NT-proBNP
repeatedly over time, which would have allowed us to
examine participants with increasing, decreasing and
stable NT-proBNP levels. Also, although we observed
associations of NT-proBNP with functional impairment
at baseline and over time, we do not know the exact
cause or pathway of this relationship. Since we primar-
ily performed a prediction study, future studies will have
to provide more etiological insight in the possible mech-
anism(s) underlying these associations. Another limita-
tion is that echocardiographic measurements or data on
physical activity or cardiorespiratory fitness are not
available. A final limitation is that the three NT-
proBNP groups were composed according to rank num-
ber, and no predefined cutoff values were applied; this
makes translation of our findings into clear-cut clinical
thresholds more difficult.
Further investigation
We recommend further studies to affirm our findings
especially with regard to NT-proBNP levels and func-
tional decline and to further explore possible clinically
relevant cutoff values. Also, intervention studies evalu-
ating the use of NT-proBNP in risk assessment in (very)
old age and monitoring subsequent cognitive, functional
and cardiovascular outcomes may reveal whether addi-
tion of NT-proBNP in risk stratification actually im-
proves prognostic accuracy. Studies investigating the
etiology of the association of NT-proBNP with ADL
functioning and cognitive impairment are tempting.
Establishing whether this association is mediated by
subclinical heart failure (and subsequent low blood
pressure), diastolic dysfunction (Suwa and Ito 2009),
intermittent atrial fibrillation (and subsequent (micro)
thromboembolisms) (Kalantarian et al. 2013), incident
cardiovascular disease, general atherosclerosis or yet
another mechanism is mandatory. Thereafter, clear
clinical implications of high-NT-proBNP levels can be
formulated.
Conclusion
In very old age, NT-proBNP is a strong predictor of
accelerated cognitive and functional decline as well as
of cardiovascular morbidity (heart failure, atrial fibrilla-
tion, myocardial infarction and stroke) and mortality.
High levels of NT-proBNP may help clinicians identify
patients who will probably benefit most from proactive
follow-up. Early detection and treatment of incident
cardiovascular disease and optimizing (secondary) pre-
ventive measures might help preserve independency.
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